<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190717044248N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-01-06</date_registration>
      <primary_sponsor>Rafsanjan University of Medical Sciences</primary_sponsor>
      <public_title>A Comparative  investigation  of the effect of oral vening primrose oil capsules with vaginal form before induction on Bishop's score, the success of induction, and some outcomes of labor.</public_title>
      <acronym></acronym>
      <scientific_title>A Comparative  investigation  of the effect of oral vening primrose oil capsules with vaginal form before induction on Bishop's score, the success of induction, and some outcomes of labor in women.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-08-04</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/48998</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random classification by minimization method:
Among those who refer to the maternity hospital to induce labor, people who have the inclusion criteria, Will be selected as a research sample. In order to allocate individuals to groups A or B, the first person in each of the quadrupled stratums will be randomly entered into the study by flip a coin. To allocate the next samples to groups A or B, the sum of the number of samples, ie the  
 number of pregnancies and the bishop score, is considered in the quadrupled stratums, and the next sample will belong to the class that has the least sum. If the samples are equal in stratums, the same routine flip a coin will be repeated, Blinding description: In order to be blind in this study, the pharmacist will put the medicines of groups A and B in the same-shape (uniform) packages and the prescription will be placed inside each package. The researcher will not know the type of medicines in these two groups. At first, the participants will be given the necessary explanations for participation and informed consent will be obtained. 
 Blinding will be performed for the statistical analyzer. After completing the statistical analysis, the pharmacist will be asked about the type of medicines of groups A or B. The clinician will not know which medicine belongs to group A or B.Vaginal examination will be performed by a clinical caregiver and the bishop score will be determined and participants will be referred to another research colleague for medication. The medicine will be given to the participant according to the number of pregnancies and bishop score with the minimization method. In the next step, the clinical caregiver who does not know about the groups of the medicines will perform the examinations two and four hours later and will record it in the file. The other research colleague will complete the checklist according to the file.</study_design>
      <phase>3</phase>
      <hc_freetext>Nornal vaginal delivery.</hc_freetext>
      <i_freetext>Intervention 1: The first intervention group will receive two Prime rose capsules  (oral,1000 mg, daily) made by Barich Essence Company, before induction. Intervention 2: The second intervention group will receive two Prime rose capsules  (vaginal,1000 mg, daily) made by Barich Essence Company, before induction.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Confidentiality of information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mahdiyehsadat Hoseinipour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 37, 27th Alley, Mostafa Khomeini Ave., Rafsanjan</address>
        <city>Rafsanjan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7714646737</zip>
        <telephone>+98 34 3422 0393</telephone>
        <email>shirinhoseinipour@yahoo.com</email>
        <affiliation>Rafsanjan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>zahra saghafi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>nursing  and midwifry scool,sahely Blvd,Motahary Street</address>
        <city>Rafsanjan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7718145056</zip>
        <telephone>+98 34 2834 7100</telephone>
        <email>zsaghafi@yahoo.com</email>
        <affiliation>Rafsanjan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Willingness for participant in the study
Willingness to  normal vaginal  delive
Mother age between 18-35 years
Normal amniotic cyst
Normal ECG of fetus
No labor contraction
Low risk pregnancy
Single-fetus
Cephalic presentation based on the latest ultrasound results
Bishop score less than 6
Iranian race
Selection of Niknafs Maternity Center of Rafsanjan as the place of delivery</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>35 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Contraindications of Gelax consumption
Sensitivity to Gelax capsules
known history of psychological illness
Delivery complications such as polyhydramnios, oligohydramnios, preeclampsia, eclampsia, vaginal bleeding
History of having confirmed psychological disorders
The need for emergency intervention for maternal or fetal reasons before induction
Birth weight less than 2500 and above 4000 grams
Having labor contractions</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Diagnosis</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The first intervention group will receive two Prime rose capsules  (oral,1000 mg, daily) made by Barich Essence Company, before induction.</i_keyword>
      <i_keyword>The second intervention group will receive two Prime rose capsules  (vaginal,1000 mg, daily) made by Barich Essence Company, before induction.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The mean of Bishop's score. Timepoint: Determination of Bishop score before induction, two and four hours after induction. Method of measurement: The Bishop score table, which has five criteria including dilatation, effacement, fetal head station, softness, and position of the cervix during  a vaginal examination. for scoring each of the first three criteria, take a score of 3-0, and each of the next two criteria, take a score of 2. -0.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>The duration of the first stage of labor. Timepoint: From the onset of the active phase of labor to the complete opening of the cervix (measurements were taken every hour). Method of measurement: Use checklist (written in the checklist every hour).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Rafsanjan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-10-09</approval_date>
        <contact_name>Ethics committee of Rafsanjan University of Medical Sciences</contact_name>
        <contact_address>Emam Ali Blvd, Rafsanjan رفسنجان Kerman Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
